- Home
- SBFM vs PALI Comparison
SBFM vs PALI Comparison
Compare SBFM & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBFM
- PALI
- Stock Information
- Founded
- SBFM 2006
- PALI 1996
- Country
- SBFM United States
- PALI United States
- Employees
- SBFM N/A
- PALI N/A
- Industry
- SBFM Biotechnology: Pharmaceutical Preparations
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SBFM Health Care
- PALI Health Care
- Exchange
- SBFM Nasdaq
- PALI Nasdaq
- Market Cap
- SBFM 6.6M
- PALI 7.5M
- IPO Year
- SBFM N/A
- PALI N/A
- Fundamental
- Price
- SBFM $1.50
- PALI $0.60
- Analyst Decision
- SBFM Strong Buy
- PALI Strong Buy
- Analyst Count
- SBFM 1
- PALI 2
- Target Price
- SBFM $15.00
- PALI $12.00
- AVG Volume (30 Days)
- SBFM 44.5K
- PALI 543.1K
- Earning Date
- SBFM 11-04-2025
- PALI 11-11-2025
- Dividend Yield
- SBFM N/A
- PALI N/A
- EPS Growth
- SBFM N/A
- PALI N/A
- EPS
- SBFM N/A
- PALI N/A
- Revenue
- SBFM $36,341,741.00
- PALI N/A
- Revenue This Year
- SBFM $32.20
- PALI N/A
- Revenue Next Year
- SBFM $32.74
- PALI N/A
- P/E Ratio
- SBFM N/A
- PALI N/A
- Revenue Growth
- SBFM 19.22
- PALI N/A
- 52 Week Low
- SBFM $1.17
- PALI $0.53
- 52 Week High
- SBFM $3.90
- PALI $4.32
- Technical
- Relative Strength Index (RSI)
- SBFM 56.84
- PALI 37.11
- Support Level
- SBFM $1.35
- PALI $0.70
- Resistance Level
- SBFM $1.45
- PALI $0.69
- Average True Range (ATR)
- SBFM 0.07
- PALI 0.04
- MACD
- SBFM 0.01
- PALI -0.00
- Stochastic Oscillator
- SBFM 82.39
- PALI 30.91
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.